Drugs / JD123
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06201247 | Dec 2023 → Dec 2025 overdue | acute myeloid leukemia | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JD123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06201247 ↗ |
| Known as | JD123 injection | “JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.” NCT06201247 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor modified natural killer cells (CAR-NK) therapy” NCT06201247 ↗ |